CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39

Xiao Zhang, Xia Ouyang, Zhenjian Xu, Junzhe Chen, Qiuyan Huang, Ya Liu, Tongtong Xu, Julie Wang, Nancy J. Olsen, Anping Xu, Song Guo ZhengMolecular 2019 · DOI

TL;DR

This study identifies CD39 as a key molecule on CD8+CD103+ regulatory T cells (iTregs) that is crucial for their ability to suppress autoimmune responses, specifically in a model of lupus nephritis. This finding not only elucidates a molecular mechanism for iTreg function but also suggests CD39 as a valuable biomarker for identifying potent therapeutic iTregs.

What Problem Does This Paper Address?

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the immune system attacking the body's own tissues. Lupus nephritis, a severe complication affecting the kidneys, significantly impacts patient prognosis. While regulatory T cells (Tregs) are known to dampen excessive immune responses, their precise roles and therapeutic potential in SLE, particularly specific subsets like CD8+ Tregs, remain areas of active investigation. Previous work by the authors demonstrated that CD8+CD103+ iTregs, generated ex vivo with TGF-β, could ameliorate autoimmune inflammation. However, the underlying molecular mechanisms driving their immunosuppressive function were not fully understood, leaving a gap in our ability to optimize their therapeutic use.

Methods

The researchers employed a multi-pronged approach combining in vitro and in vivo experiments.

  • RNA Sequencing (RNA-seq): To identify differentially expressed genes between CD8+CD103+ iTregs and CD8+CD103- cells, providing initial clues about functional differences.
  • Flow Cytometry: Used extensively to analyze cell surface marker expression (CD103, CD39, CD4, CD8) and intracellular cytokine production (IL-17a, IFN-γ).
  • In Vitro Suppression Assays: Co-culturing iTregs with T responder cells to assess their ability to inhibit T cell proliferation and differentiation. This involved using a CD39 inhibitor (ARL 67156) to probe the role of CD39.
  • Chronic Graft-versus-Host Disease (cGVHD) Lupus Nephritis Mouse Model: A well-established model was used to evaluate the therapeutic efficacy of iTregs in vivo. This involved adoptive transfer of iTregs and assessment of disease markers like proteinuria, autoantibodies (anti-dsDNA, IgG), and kidney pathology.
  • Cell Sorting: FACSAria III was used to isolate specific iTreg subpopulations (CD39+ vs. CD39-) for functional testing.
  • Histological and Immunofluorescence Analysis: Kidney tissues were examined to assess the severity of nephritis and immune complex deposition.
  • Human Peripheral Blood Mononuclear Cell (PBMC) Analysis: To assess the clinical relevance of the findings, CD8+ T cell populations from lupus patients and healthy controls were analyzed for CD103 and CD39 expression. Naive CD8+ T cells from healthy donors were also induced into iTregs ex vivo to study CD39 expression and function.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from mouse models and human blood samples.

Key Insights and Ideas

  • CD39 as a Key Player: The study strongly implicates CD39 as a critical mediator of the immunosuppressive function of CD8+CD103+ iTregs. Its increased expression on these cells appears to be directly linked to their ability to dampen autoimmune responses.
  • CD39 as a Biomarker: The consistent expression of CD39 on functional CD8+CD103+ iTregs, and its correlation with therapeutic efficacy, positions it as a promising phenotypic biomarker for identifying highly qualified iTregs for therapeutic applications.
  • Mechanism of Action: While not fully detailed, the study suggests that CD39's role in ATP/adenosine metabolism might be a key mechanism by which iTregs exert their immunosuppressive effects, particularly in the context of lupus nephritis.
  • Clinical Relevance: The findings in human PBMCs suggest that the observed dysregulation of CD8+ T cell subsets (including CD39 expression) in lupus patients may contribute to disease pathogenesis, and that human iTregs also rely on CD39 for their suppressive function.

Key Results

  • Therapeutic Efficacy of iTregs: Adoptive transfer of CD8+CD103+ iTregs significantly ameliorated lupus nephritis in a mouse model, reducing proteinuria, autoantibody levels, and kidney pathology.
  • CD39 Upregulation: RNA-seq revealed a significant upregulation of Entpd1 (coding for CD39) in CD8+CD103+ iTregs compared to CD8+CD103- cells. Flow cytometry confirmed higher CD39 protein expression on iTregs.
  • CD39 Inhibition Impairs Function: Administration of a CD39 inhibitor (ARL 67156) significantly abolished the immunosuppressive capacity of CD8+ iTregs both in vitro (on T cell proliferation and differentiation) and in vivo (reducing their therapeutic effect on lupus nephritis).
  • CD39+ iTregs are More Potent: Sorted CD8+CD103+CD39+ iTregs demonstrated superior therapeutic efficacy in treating lupus nephritis compared to CD39- iTregs or iTregs pretreated with a CD39 inhibitor.
  • Human CD8+ iTregs: Human CD8+ iTregs also showed increased CD103 and CD39 expression, and CD39 was involved in their suppressive function, highlighting translational potential.
  • Lupus Patients: Lupus patients exhibited decreased percentages of CD8+ T cells expressing CD103 or CD39 compared to healthy controls.

Limitations and Future Work

  • Animal Model vs. Human SLE: While the study provides strong evidence in a mouse model and supports it with human PBMC data, the full complexity of human SLE and its response to iTreg therapy requires further investigation.
  • Specific Mechanism of CD39: The precise molecular pathways through which CD39 mediates immunosuppression (e.g., adenosine generation, direct cell-cell interactions) warrant deeper exploration.
  • Other Markers: While CD39 is highlighted, the authors acknowledge that other molecules might also contribute to the immunosuppressive function of CD8+CD103+ Tregs.
  • Clinical Translation: Further studies are needed to optimize the generation and application of CD39-expressing CD8+ iTregs for clinical use in SLE patients and other autoimmune diseases. The authors suggest that manipulating CD8+CD103+CD39+ cells holds therapeutic promise.

Summary updated

Abstract

Many patients with systemic lupus erythematosus (SLE) have lupus nephritis, one of the severe complications of SLE. We previously reported that CD8+CD103+ T regulatory cells induced ex vivo with transforming growth factor β (TGF-β) (iTregs) inhibited immune cells responses to ameliorate excessive autoimmune inflammation. However, the molecular mechanism(s) underlying the role of these CD8+ iTregs is still unclear. Here we identified that CD39, which is highly expressed on CD8+ iTregs, crucially contributes to the immunosuppressive role of the CD8+CD103+ iTregs. We showed that adoptive transfer of CD8+CD103+ iTregs significantly relieves the chronic graft-versus-host disease with lupus nephritis and CD39 inhibitor mostly abolished the functional activities of these CD8+ iTregs in vitro and in vivo. CD39+ cells sorted from CD8+CD103+ iTregs were more effective in treating lupus nephritis than CD39- partner cells in vivo. Furthermore, human CD8+ iTregs displayed increased CD103 and CD39 expressions, and CD39 was involved in the suppressive function of human CD8+ iTregs. Thus, our data implicated a crucial role of CD39 in CD8+CD103+ iTregs in treating lupus nephritis, and CD39 could be a new phenotypic biomarker for the identification of highly qualified CD8+ Tregs. This subpopulation may have therapeutic potential in patients with SLE nephritis and other autoimmune diseases.
BibTeX
@inproceedings{zhang2019cd,
  author = {Xiao Zhang and Xia Ouyang and Zhenjian Xu and Junzhe Chen and Qiuyan Huang and Ya Liu and Tongtong Xu and Julie Wang and Nancy J. Olsen and Anping Xu and Song Guo Zheng},
  title = {{CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.1016/j.ymthe.2019.07.014},
}
Figure